Опыт применения ритуксимаба у детей с системной красной волчанкой: ретроспективное исследование серии случаев
https://doi.org/10.15690/vsp.v15i3.1567
Аннотация
Системная красная волчанка (СКВ) у детей отличается непредсказуемым и тяжелым течением. Стандарта терапии заболевания в настоящее время не существует. В статье представлены результаты ретроспективного исследования эффективности ритуксимаба у 16 детей с СКВ в возрасте от 5 до 16 лет, находившихся на стационарном лечении. Ритуксимаб назначали пациентам с тяжелым жизнеугрожающим течением болезни при неэффективности гормонально-цитостатической терапии или невозможности снижения суточной дозы кортикостероидов. Доза вводимого препарата составляла 375 мг/м2 еженедельно в течение 4 нед. На фоне терапии ритуксимабом отмечено клинически значимое снижение значений лабораторных показателей активности заболевания, индексов активности болезни SLEDAI, ECLAM, индекса повреждения SLICC/ACR, а также суточной дозы кортикостероидов. Зафиксированы один случай пневмонии и 2 летальных исхода, наступивших на фоне присоединения генерализованной микотической инфекции.
Об авторах
М. М. Костик
Санкт-Петербургский государственный педиатрический медицинский университет, Санкт-Петербург, Российская Федерация
Россия
Россия
кандидат медицинских наук, доцент кафедры госпитальной педиатрии Санкт-Петербургского государственного педиатрического медицинского университета Адрес: 194100, Санкт-Петербург, ул. Литовская, д. 2, тел.: +7 (812) 416-52-98
Е. М. Кучинская
Санкт-Петербургский государственный педиатрический медицинский университет, Санкт-Петербург, Российская Федерация
Россия
Россия
Ф. Н. Абдурагимова
Санкт-Петербургский государственный педиатрический медицинский университет, Санкт-Петербург, Российская Федерация
Россия
Россия
О. П. Гурина
Санкт-Петербургский государственный педиатрический медицинский университет, Санкт-Петербург, Российская Федерация
Россия
Россия
О. В. Калашникова
Санкт-Петербургский государственный педиатрический медицинский университет, Санкт-Петербург, Российская Федерация
Россия
Россия
В. Г. Часнык
Санкт-Петербургский государственный педиатрический медицинский университет, Санкт-Петербург, Российская Федерация
Россия
Россия
Список литературы
1. Chiang LL, Lin YT, Chan HY, Chiang BL. Differential manifestations of prepubescent, pubescent and postpubescent pediatric patients with systemic lupus erythematosus: A retrospective study of 96 Chinese children and adolescents. Pediatr Rheumatol Online J. 2012;10(1):12. doi: 10.1186/1546-0096-10-12.
2. Medina-Quinones CV, Ramos-Merino L, Ruiz-Sada P, Isenberg D. Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period. Arthritis Care Res (Hoboken). 2016;68(7):981–987. doi: 10.1002/acr.22774.
3. Carreno L, Lopez-Longo FJ, Monteagudo I, et al. Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus. 1999;8(4):287– 292. doi: 10.1191/096120399678847786.
4. Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Rheumatology (Oxford). 1995;34(9):866–872. doi: 10.1093/rheumatology/ 34.9.866.
5. Tucker LB, Uribe AG, Fernandez M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008;17(4):314–322. doi: 10.1177/0961203307087875.
6. Brunner HI, Gladman DD, Ibanez D, et al. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58(2):556–562. doi: 10.1002/art.23204.
7. Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus. 2001;10(3):140–147. doi: 10.1191/096120301675075008.
8. Dan D, Fischer R, Adler S, et al. Cyclophosphamide: As bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases. Swiss Med Wkly. 2014;144:w14030. doi: 10.4414/smw.2014.14030.
9. Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus. 2004;13(9):673–678. doi: 10.1191/096120 3304lu2012oa.
10. Feng L, Deng J, Huo DM, et al. Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis. Nephrology (Carlton). 2013;18(2):104–110. doi:10.1111/nep.12006.
11. Grammer AC, Lipsky PE. B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther. 2003;5(Suppl 4):S22–27. doi: 10.1186/ar1009.
12. Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011;30(9):1163– 1172. doi: 10.1007/s10067-011-1720-7.
13. Cooper MA, Willingham DL, Brown DE, et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007;56(9):3107– 3111. doi: 10.1002/ art.22856.
14. Kavcic M, Fisher BT, Seif AE, et al. Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children’s hospitals across the United States. J Pediatr. 2013;162(6):1252–1258.e1. doi: 10.1016/j.jpeds.2012.11.038.
15. Clain JM, Specks U. S1. Rituximab for ANCA-associated vasculitis: the experience in the United States. Presse Med. 2013; 42(4 Pt 2):530–532. doi: 10.1016/j.lpm.2013.01.048.
16. Tambralli A, Beukelman T, Cron RQ, Stoll ML. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases. J Rheumatol. 2015;42(3):541–546. doi: 10.3899/jrheum.140863.
17. Watson L, Beresford MW, Maynes C, et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus. 2015;24(1):10–17. doi: 10.1177/0961203314547793.
18. Lehman TJ, Singh C, Ramanathan A, et al. Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J. 2014;12:3. doi: 10.1186/1546- 0096-12-3.
19. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928.
20. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306. doi: 10.1111/j.1538-7836.2006.01753.x.
21. Lam GK, Petri M. Assessment of systemic lupus erythematosus. Clin Exp Rheumatol. 2005;23(5 Suppl 39):120–132.
22. Van Blerk M, Bossuyt X, Humbel R, et al. Belgian recommendations on ANA, anti-dsDNA and anti-ENA antibody testing. Acta Clin Belg. 2014;69(2):83–86. doi: 10.1179/2295333714Y.0000000010.
23. rlsnet.ru [интернет]. Ритуксимаб (Rituximab): инструкция, применение и формула. Регистр лекарственных средств России. 2007 [доступ от 19.05.2016]. Доступ по ссылке: http://www.rlsnet.ru/mnn_index_id_2695.htm.
24. Асеева Е.А., Соловьев С.К., Насонов Е.Л. Современные методы оценки активности системной красной волчанки // Научно-практическая ревматология. — 2013. — Т.51. — №2. — С. 186– 200. [Aseeva EA, Solovyev SK, Nasonov EL. Current methods for evaluating the activity of systemic lupus erythematosus. Sciencepractical rheumatology. 2013;51(2):186–200. (In Russ).]
25. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the sledai. A disease activity index for lupus patients. Arthritis Rheum. 1992;35(6):630–640. doi: 10.1002/art.1780350606.
26. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group‘s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005;44(7):902– 906. doi: 10.1093/rheumatology/keh624.
27. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989;32(9): 1107–1118. doi: 10.1002/anr.1780320909.
28. Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol. 2000;27(3):664–670.
29. Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol. 1992;19(1):53–59.
30. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response C. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum. 2004;50(11):3418–3426. doi: 10.1002/art.20628.
31. Ruperto N, Ravelli A, Cuttica R, et al. The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. Arthritis Rheum. 2005;52(9):2854–2864. doi: 10.1002/art.21230.
32. Ruperto N, Bazso A, Pistorio A, et al. Agreement between multidimensional and renal- specific response criteria in patients with juvenile systemic lupus erythematosus and renal disease. Clin Exp Rheumatol. 2010;28(3):424–433.
33. Mosca M, Bencivelli W, Vitali C, et al. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus. 2000;9(6):445–450. doi: 10.1191/096120300678828640.
34. Brunner HI, Silverman ED, Bombardier C, Feldman BM. European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 2003;49(3):335–341. doi: 10.1002/art.11111.
35. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363–369. doi: 10.1002/art.1780390303.
36. Gutierrez-Suarez R, Ruperto N, Gastaldi R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2989–2996. doi: 10.1002/art.22048.
37. Novikova DS, Popkova TV, Lukina GV, et al. The Effects of Rituximab on Lipids, Arterial Stiffness and Carotid Intima-Media Thickness in Rheumatoid Arthritis. J Korean Med Sci. 2016;31(2): 202–207. doi: 10.3346/jkms.2016.31.2.202.
38. Nwobi O, Abitbol CL, Chandar J, et al. Rituimab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol. 2008;23(3):413–419. doi: 10.1007/s00467-007-0694-9.
39. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. 2005;52(10):3168–3174. doi: 10.1002/ art.21351.
40. Trachana M, Koutsonikoli A, Farmaki E, et al. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece. Rheumatol Int. 2013;33(3):809–813. doi: 10.1007/s00296-011-2239-6.
41. Moroni G, Raffiotta F, Trezzi B, et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology (Oxford). 2014;53(9):1570–1577. doi: 10.1093/rheumatology/ket462.
42. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA- associated vasculitis. N Engl J Med. 2010; 363(3):221–232. doi: 10.1056/NEJMoa0909905.
43. Fernandez-Nebro A, de la Fuente JL, Carreno L, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus. 2012;21(10):1063–1076. doi: 10.1177/0961203312446627.
44. Costa-Reis P, Nativ S, Isgro J, et al. Major infections in a cohort of 120 patients with juvenile-onset systemic lupus erythematosus. Clin Immunol. 2013;149(3):442–449. doi: 10.1016/j.clim.2013.08.009.
45. Kamanamool N, McEvoy M, Attia J, et al. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore). 2010;89(4):227–235. doi: 10.1097/MD.0b013e3181e93d00.
46. Houssiau FA, D’Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69(12):2083-2089. doi: 10.1136/ard.2010.131995.
47. fda.gov [Internet]. Rituxan® (rituximab). Highlights of prescribing information [cited 2016 May 19]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103705s5414lbl.pdf.
Рецензия
Для цитирования:
Костик М.М., Кучинская Е.М., Абдурагимова Ф.Н., Гурина О.П., Калашникова О.В., Часнык В.Г. Опыт применения ритуксимаба у детей с системной красной волчанкой: ретроспективное исследование серии случаев. Вопросы современной педиатрии. 2016;15(3):295-300. https://doi.org/10.15690/vsp.v15i3.1567
For citation:
Kostik M.M., Kuchinskaya E.M., Abduragimova F.N., Gurina O.P., Kalashnikova O.V., Chasnyk V.G. Experience in Rituximab Administration in Children with Systemic Lupus Erythematosus: a Retrospective Study of the Case Series. Current Pediatrics. 2016;15(3):295-300. (In Russ.) https://doi.org/10.15690/vsp.v15i3.1567
Просмотров: 825
Послать статью по эл. почте 
